AGI Biopharmaceuticals, Ltd., a European firm that has developed a patented, economic, melanoma vaccine with future multi-cancer application, has raised $4.71m in equity funding from Mentor Capital, Inc. (OTC Markets: MNTR).
With the funding, Mentor has purchased a 30% ownership in AGI.
The company intends to use the capital to support final trials leading to commercialization.
Since 1995, AGI Biopharmaceuticals has conducted six human trials with their molecular key fitting in approximately 30% of the melanoma cases.
FinSMEs
28/11/2011